Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2008
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00047736 (A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Guideline
- EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Trial
- A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.Breast cancer research and treatment · 2012Trial
- Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.Lancet (London, England) · 2011Trial
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.Gynecologic oncology · 2011Trial
- Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Trial
- Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Cancer medicine · 2017Article
- Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.Translational lung cancer research · 2015Article
- EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011Article
- Synchronous lung cancers: when same histological types feature different molecular profiles and response phenotypes.Journal of Cancer · 2011Article
- Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2011Review
- Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Critical reviews in oncology/hematology · 2010Review
- [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Review
- [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2010Article
- Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.Journal of thoracic disease · 2010Article
- Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Article
- Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer.Therapeutic advances in medical oncology · 2009Article
- EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.Journal of clinical pathology · 2009Article
- Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTRIBUTE was a phase III trial evaluating the addition of erlotinib to carboplatin and paclitaxel as a first-line treatment for advanced non-small cell lung cancer that did not meet its primary end point of improving overall survival. Here, we assess the value of using epidermal growth factor receptor (EGFR) gene copy number in tumor biopsy samples, as determined by fluorescence in situ hybridization (FISH), as a predictor of treatment outcome.
methodsEGFR FISH analysis was done using LSI EGFR SpectrumOrange/CEP7 SpectrumGreen probe.
resultsOf 275 samples, 245 (89.1%) were successfully analyzed by FISH. One hundred (40.8%) of patients were EGFR FISH(+). Median overall survival was not different between FISH(+) and FISH(-) patients in either the chemotherapy+erlotinib arm or the chemotherapy+placebo arm. In FISH(+) patients, median time to progression (TTP) was 6.3 months in the erlotinib arm versus 5.8 months in the placebo arm (hazard ratio, 0.59; 95% confidence interval, 0.35-0.99; P = 0.0430); in FISH(-) patients, median TTP was 4.6 months versus 6.0 months (hazard ratio, 1.42; 95% confidence interval, 0.95-2.14; P = 0.0895; treatment interaction test, P = 0.007). After 6 months of treatment, a notable separation of the TTP curves in favor of erlotinib emerged. Objective response rates were 11.6% versus 29.8% in FISH(+) patients (chemotherapy+erlotinib arm versus chemotherapy+placebo arm; P = 0.0495) and 21.8% versus 25.4%, respectively, for FISH(-) patients (P = 0.6954).
conclusionsEGFR gene copy number by FISH did not predict survival benefit. However, among EGFR FISH(+) patients, TTP was longer in patients who received erlotinib and continued to receive it after completing first-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.